Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again, making it possible for the official mascots to eat breakfast on the deck and take long naps. As for us, we are firing up the coffee kettle to make another cup of stimulation.
Our choice today is hot buttered rum, an old standby. Meanwhile, here is the latest menu of tidbits to help you on your journey. We hope you have a meaningful and productive day and, of course, do stay in touch.
… Eli Lilly reported more results showing its next-generation obesity drug is highly effective at weight loss, but data from the study, focused on people with heart disease, are not enough to answer a critical question — whether it reduces cardiovascular risk, STAT points out. The Phase 3 study enrolled nearly 2,000 people with severe obesity and heart disease, with or without diabetes. Those on the highest dose of the drug, called retatrutide, lost 22.6% of their weight after 80 weeks, while those on placebo lost 3.2%, when analyzing only participants who stayed on treatment.
However, on prespecified analyses that looked at the occurrence of major cardiovascular events such as death, heart attack, or stroke, those taking retatrutide did not have a statistically significant lower risk of major events than those on placebo. Many patients have opted for injectable forms of the popular GLP-1 obesity medications through a pilot program of the U.S. government’s Medicare health insurance program for Americans aged 65 and older, Reuters says.
Centers for Medicare & Medicaid Services this month launched an 18-month trial program that for the first time opens access to Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound as weight loss treatment alone for a monthly cost of $50. Millions of people are expected to qualify, and doctors are being flooded with interest from patients. Many pharmaceutical industry experts had expected that patients would prefer pills over injections, for convenience, but 8 of 10 doctors interviewed and three pharma sector analysts said many are opting for injectables.Continue to STAT+ to read the full story…
Eli Lilly reported more results Thursday showing that its next-generation obesity drug is highly efficacious at weight loss, but the data from the study, focused on people with heart disease, aren’t enough to answer a critical question about the therapy — whether it reduces cardiovascular risk. Lilly said the trial was not powered to study cardiovascular outcomes and there were fewer heart events than anticipated.Continue to STAT+ to read the full story…
Summary from source